Harmony Biosciences Holdings, Inc. (HRMY) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Harmony Biosciences Holdings, Inc.'s filing signal continuing positive.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing treatments for rare neurological diseases. Its primary product, WAKIX (pitolisant), is a first-in-class therapy for narcolepsy, approved for excessive daytime sleepiness (EDS) and cataplexy in adults and pediatric patients. The company is expanding its pipeline through late-stage clinical programs for pitolisant in Prader-Willi syndrome and myotonic dystrophy type 1, and through acquisitions and licensing of other neurological disease candidates. Harmony operates in a single segment focused on rare neurological diseases, with all revenue currently derived from WAKIX sales in the United States.

Revenue is driven by the sales of WAKIX, a treatment for narcolepsy. Net product revenue for the year ended December 31, 2025, was $868.5 million, representing an increase of 21.5% from the prior year, attributed to higher unit shipments and a price increase, partially offset by higher rebates.